Trials / Completed
CompletedNCT00945035
Study of the Bioequivalence of the 20% and 30% Etoricoxib Tablet Formulations (0663-070)
An Open-Label, Randomized, 2-Period, Single-Dose, Balanced, Crossover Study in Healthy Subjects to Establish the Bioequivalence of the 20% and 30% Etoricoxib (MK0663) Formulations
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This study will establish the bioequivalence of the 20%, milled, roller compaction final market image (FMI) etoricoxib tablets and 30% unmilled, roller compaction (UMC) etoricoxib tablets.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | etoricoxib | Single dose etoricoxib 120 mg 20% final market image tablet in one of two treatment periods. |
| DRUG | Comparator: etoricoxib | Single dose etoricoxib 120 mg 30% unmilled, roller compaction tablet in one of two treatment periods. |
Timeline
- Start date
- 2002-11-01
- Primary completion
- 2002-12-01
- Completion
- 2002-12-01
- First posted
- 2009-07-23
- Last updated
- 2022-02-09
- Results posted
- 2009-11-17
Source: ClinicalTrials.gov record NCT00945035. Inclusion in this directory is not an endorsement.